Neuroleptic malignant syndrome and atypical antipsychotic drugs.

  title={Neuroleptic malignant syndrome and atypical antipsychotic drugs.},
  author={J. Ananth and S. Parameswaran and S. Gunatilake and K. Burgoyne and Taghrid Sidhom},
  journal={The Journal of clinical psychiatry},
  volume={65 4},
  • J. Ananth, S. Parameswaran, +2 authors Taghrid Sidhom
  • Published 2004
  • Medicine
  • The Journal of clinical psychiatry
  • OBJECTIVE The incidence of neuroleptic malignant syndrome (NMS) is not known, but the frequency of its occurrence with conventional antipsychotic agents has been reported to vary from 0.02% to 2.44%. DATA SOURCES MEDLINE search conducted in January 2003 and review of references within the retrieved articles. DATA SYNTHESIS Our MEDLINE research yielded 68 cases (21 females and 47 males) of NMS associated with atypical antipsychotic drugs (clozapine, N = 21; risperidone, N = 23; olanzapine, N… CONTINUE READING
    222 Citations
    Clozapine-induced neuroleptic malignant syndrome in an adolescent.
    • K. Matheson, G. Gray
    • Psychology, Medicine
    • Journal of child and adolescent psychopharmacology
    • 2012
    • 3
    • Highly Influenced
    Olanzapine-Induced Neuroleptic Malignant Syndrome
    • 3
    Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?
    • 34
    • PDF
    Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
    • 58
    • PDF


    Risperidone-Induced Neuroleptic Malignant Syndrome: A Case Report and Review
    • G. Meterissian
    • Psychology, Medicine
    • Canadian journal of psychiatry. Revue canadienne de psychiatrie
    • 1996
    • 31
    Neuroleptic malignant syndrome associated with olanzapine therapy: a case report.
    • 35
    Neuroleptic malignant syndrome associated with clozapine treatment.
    • 37
    Risperidone and neuroleptic malignant syndrome.
    • 18
    Clozapine-induced neuroleptic malignant syndrome: review and report of new cases.
    • 133
    Clinical Management of Neuroleptic Malignant Syndrome
    • 83